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Abstract  
Objective: To see the clinical features and treatment of children with Acute Myeloid Leukemia 
(AML) in Pakistan. Setting: Tertiary referral at a specialist Hematology/Oncology center. 
Methods: Retrospective, chart-based review of children (less than 14 years) admitted to the 
hospital with a diagnosis of AML between January 1987 and August 1997. 
Results: A total of 23 patients were admitted. There were 18 males and 5 females. The mean age 
was 8 5 years. M3 was the commonest morphological subtype (43%). Twenty- two percent of 
the patients presented with hyperleucocytosis (TLC> 100 x i09 /L) and 95% with an elevated 
LDH (>548 lUlL). Pneumonia at presentation was seen in 29%. Of 23 patients 14 were evaluable 
for responses. Six patients died early (43%); 3 before starting the chemotherapy and 3 during the 
induction chemotherapy, 8/11 (73%) patients entered remission. The median survival was 9 
months. 
Conclusion: The pediatric patients with acute myeloid leukemia present with advanced disease. 
There is a high early death rate (within 28 days of diagnosis). The long-term outcome was 
inferior to that reported in the literature (JPMA 52:247; 2002). 
Introduction  
Acute leukemia is the commonest childhood cancer, however, acute myeloid leukemia (AML) 
constitutes only 15 to 20% of such cases1. Whereas, acute lymphohiastic leukemia (ALL) is 
curable in vast majority of cases2, the long-tere survivil of AML in chiddren is(only 30(to 
40%,(even with curreft chemotherapy protocols and intensive supportie care3. I-lowevez these 
figures originatni from the data nrom a different background of patients,(where t’e biological 
nature of he diseise may also be different4. Furthermore, the nutritional and socioeconomic 
circumstances of the children reported in those studies are different compared to our part of the 
world. Such factors are also known to affect the outcomes5. Information about the 
clinicopathological features of AML has started to emerge from the developing countries5-7. This 
report is a compilation of our experience over the past 10 years in a major hematology and 
oncology center in southern Pakistan. 
Patients and Methods  
The data were collected retrospectively. The clinical records of consecutive patients diagnosed to 
have AML between January 1987 and August 1997 and under the age of 14 years were retrieved 
by the medical record section. The diagnosis is logged on the face sheet of the medical charts by 
the attending physicians. The medical records department uses International Classification of 
Disease Version 9 database (lCD 9.0). The survival curve was generated according to the method 
of Kaplan and Meier8. 
Results  
Over 10 years, a total of 281 patients under the age of 14 years were admitted to the hospital with 
an underlying diagnosis of acute leukemia. Of these, 258 were diagnosed to have ALL, whereas, 
only 23 were diagnosed to have AML. This gives a ratio of 11.2: 1. The patients diagnosed to 
have AML are the subjects of this study. 
The mean age at presentation of these patients was 8 ±. 5 yrs. They were 1 8 males and 5 
females, the ratio being 3.6: 1. Majority of patients presented with fever (n=19) followed by 
bleeding (n=10), anemia (n=8) and clinically documented infection (n=5). The mean duration of 
symptoms were 39, 20, 89 and 19 days respectively. 
 Table I shows the morphological subtypes according to the French-American-British Board 
(FAB) Criteria. The commonest morphological subtype was M3 (43%) followed by M4, Ml and 
M2. 
 
 Table 2 shows various laboratory features at presentation. The mean hemoglobin at presentation 
was 7.7±2.6 g/dl. Ten patients (43%) had a hemoglobin of less than 7 g/dl. Mean total leukocyte 
count (TLC) was 48 ±51 x 109/L, 5 patients (22%) had hyperleucocytosis i.e. TLC more than 
100 x 109/L. Nine patients (3 9%) presented with severe thrombocytopenia (platelet count of less 
than 20 x 1 09/L). Ten patients (43%) had coagulation abnormalities, 2 (8%) abnormal liver 
function tests and 95% presented with Lactate Dehydrogenase (LDH) levels in excess of 548 
lU/L. The mean LDI-T was 1833 ± 1396 lUlL. The chest X-ray was available in 19/23 patients 
and signs of pneumonia at the time of presentation were present in 29% patients. 
Fourteen out of twenty three patients (14/23) were evaluable for the follow up, the rest were 
either refered or got themselves refered out of the hospital for various reasons. Three patients 
died before they could be started on induction chemotherapy. All had clinically documented 
infection, fever and 2/3 had coagulation abnormalities. Nine patients were treated with standard 
induction chemotherapy regimens consisting of cytosine arabinoside 100 mg/m2 for 7 days and 
duanorubicin 45 mg/rn2 for 3 days. Etoposide 100 mg/m22 for 4 days was added to the regimen 
of I patient who had acute monocytic leukemia. Two patients with acute promyelocytic leukemia 
received induction treatment with All Trans Retinoic acid (ATRA) at a dose of 45 mg/m2 in two 
divided doses. In all, 39 cycles of chemotherapy were administered. The post-remission therapy 
consisted of two cycles of cytosine arabinoside 100 mg/m2 for 5 days and duanorubicin 45 
mg/m2 for 2 days followed by 2 - 3 cycles of cytosine arabinoside 1.5 g/m2 12 hourly for 3 days. 
Febrile neutropenia necessitating hospitalization occurred in 18 instances following 39 cycles of 
chemotherapy (46%). The mean onset of neutropenia was 9+5 days from the start of 
chemotherapy and mean duration of the neutropenia was 8 ± 5 days. Granulocyte macrophage 
colony stimulating factor (GM-CSF) was used in 5 of these episodes. 
Three patients died before they could be started on chemotherapy and 3 died during the induction 
phase. Eight treated with chemotherapy entered remission (73%). The disease status was 
evaluated on 3 1st December 2000. In all 13 patients have died, whereas, 1 was alive in complete 
remission at 30 months. This patient had received allogenic bone marrow transplantation in 
remission. The median survival for all patients was 9 months. (Figure).  
 
Discussion 
Over the past 10 years, AML was found to constitute 9% of all acute leukemias in children under 
the age of 14 years. This figure is at variance from the figures quoted in the literature, which 
suggest that AML constitutes 15 to 20% of acute leukemias in pediatric age group9,10. Zahid et al 
reported AML in 16% of all the leukemias in a study of 62 patients from Pakistan5. The 
commonest morphological subtype in our population was M3, which was seen in 10 patients. 
This is at variance again with the western figures quoted in the literature9,10. However because of 
small number of patients in our study, it may be difficult to comment whether this observation is 
significant or not. 
Five out of 23 patients presented with hyperleukocytosis, which is known to be a poor prognostic 
indicator11. Of the six patients who died early, i.e. during the first 28 days of treatment, two 
presented with hyperleucocytosis. Majority (95%) of the patients presented with a high LDH, 
which is also an adverse prognostic sign. Taken together these findings show children in this 
study clearly presented with advanced disease and with poor prognostic features. The reasons for 
late presentation could be several but remain speculative. Bennett et a! have shown that Black 
patients present with advanced disease compared with the White because of financial reasons12. 
Similar factors are applicable in our patient population. Additionally lack of awareness of the 
severity of the disease and remoteness of specialist medical care could be the other reasons for 
late presentation. 
The two patients with M3 subtypes were treated with all trans retinoic acid (ATRA) till 
achieving complete remission. ATRA induces remission by causing cellular differentiation in 
patients with acute promyelocytic leukemia13. These patients were subsequently treated with 
standard post remission chemotherapy. The two patients relapsed at 26 and 28 months following 
the diagnosis and died. 
Most (73%) of the patients achieved remission, this includes two patients treated with ATRA. 
This figure is consistent with other published studies. Wells et al reported a complete remission 
rate (CR) of 79% for an induction regimen similar to that used in our patients3 and Creutzig et al 
reported a CR rate of 82%14. The three patients who did not achieve remission died during the 
neutropenic phase following induction chemotherapy. If three patients who died before induction 
chemotherapy could be begun were included (intent-to-treat analysis), 57% patients achieved 
remission. Taken together, six patients (43%) died within 28 days after the diagnosis was 
established. Thus from this analysis, it appears that remission rates could improve if early deaths 
could be prevented. 
The 2-year survival of2l% is inferior to some of the more recently published studies which have 
reported higher overall survival rates. Stevens et al. reported a 7-year survival of 56% in 359 
patients entered on to the Medical Research Council (MRC) 10 protoco15. It should be noted that 
the patients reported in this study received more aggressive treatment as compared to patients in 
our small series. The patients received thioguanine or etoposide in addition to cytarabine plus 
anthracycline induction and consolidation treatment and furthermore some patients also received 
auto or allogeneic bone marrow transplantation depending on the availability of donor. More 
recently, the German investigators using high dose cytarabine and mitoxantrone after 
intensification reported a 5 year survival of 60% in the AML-BFM 93 study14. The improvement 
in survival was more marked amongst the high risk patients and in whom less intensive 
daunorubicin treatment was used as part of induction treatment. 
In conclusion, children with AML in our part of the world present with advanced disease, have a 
higher chance of early death and median overall survival of nine months. Strategies need to be 
developed to deal with several issues, including the problem of late presentation, the early 
treatment of infections at the time of presentation. and reintensification with high dose 
chemotherapy. 
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